Ribo Newsroom
-
Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024August 31, 2024 -
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNAInnovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.April 8, 2024 -
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesBoehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesJanuary 3, 2024 -
Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9December 25, 2023 -
Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023April 20, 2023 -
Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in AustraliaSuzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.February 9, 2023